Aktienanalyse zu Enovis Corp (ENOV)ENOVEnovis Corp

Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX). It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Enovis Corp (ENOV) is a good buy right now due to its current price of $21.08, which is significantly lower than the average analyst price target of $41.58, suggesting a potential upside of 97.8%. Additionally, the stock has shown a positive momentum with a 5-day change of +7.61% and insider buying activity increasing by 372.22% over the last month, indicating strong confidence from management. However, the main risk is the company's net loss of $1.1 billion, which highlights ongoing profitability challenges.